A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination With Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor
Latest Information Update: 04 Jul 2025
At a glance
- Drugs Darolutamide (Primary) ; Exemestane (Primary) ; Leuprorelin (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
Most Recent Events
- 27 Jun 2025 Status changed from suspended to active, no longer recruiting.
- 27 Apr 2024 Status changed from recruiting to suspended due to scheduled interim monitoring
- 08 Feb 2024 Planned initiation date changed from 2 Feb 2024 to 18 Oct 2024.